idarubicin has been researched along with gossypol in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, S; Chen, K; Chen, XL; Feng, L; Fu, G; Jiang, S; Lin, C; Xu, B; Yang, Q; Zhang, L; Zhao, H; Zhou, Y | 1 |
1 other study(ies) available for idarubicin and gossypol
| Article | Year |
|---|---|
Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Case-Control Studies; Cell Proliferation; DNA Repair; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Gossypol; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Prognosis; RUNX1 Translocation Partner 1 Protein; Survival Rate; Synthetic Lethal Mutations; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Young Adult | 2019 |